Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Zolpidem prescribing practices before and after Food and Drug Administration required product labeling changes

Open access
Norman, Jessica L, Fixen, Danielle R, Saseen, Joseph J, Saba, Laura M, Linnebur, Sunny A · 2017 · SAGE Open Medicine

Abstract

Background: Women have higher morning serum zolpidem concentrations than men after taking an evening dose, potentially leading to increased risk of harm. On 19 April 2013, the United States Food and Drug Administration required labeling changes for zolpidem, recommending an initial dose of no greater than 5 mg (immediate release) or 6.25 mg (controlled release) per night in women. Objectives: The primary objective of this study was to compare prescribing practices before and after the 2013 zolpidem labeling change. A secondary objective was to evaluate serious adverse events potentially related to zolpidem. Methods: Electronic medical records of adults receiving care through the University of Colorado Health system were accessed for study inclusion if patients were provided a first-time prescription for zolpidem either prior to or after the Food and Drug Administration labeling change. Patients were randomly chosen from eight strata based on age, gender, and date of zolpidem initiation (before/after the labeling change). Demographic and zolpidem prescribing data were collected. Low-dose zolpidem was considered 5 mg (immediate release) or 6.25 mg (controlled release) daily or less. Documentation of potentially related serious adverse events within the patients’ records was also evaluated. Results: A total of 400 patients were included in the study. The overall percentage of patients prescribed low-dose zolpidem increased from 44% to 58% after the labeling change (p = 0.0020). In a pre-specified subgroup analysis, the percentage of patients prescribed low-dose zolpidem increased in all groups, including young men (38%–50%, p = 0.23), elderly men (34%–40%, p = 0.53), and elderly women (60%–74%, p = 0.14), but the change was only significant in young women (42%–70%, p = 0.0045). Conclusion: After Food and Drug Administration–mandated labeling changes for zolpidem in 2013, the percentage of overall patients in our health system, and specifically young women, with initial prescriptions for low-dose zolpidem significantly increased as compared to before the labeling change.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1177/2050312117707687

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Percentage of patients prescribed low-dose zolpidem.
Figure 1. Percentage of patients prescribed low-dose zolpidem.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 14 references

Research works printed but not linked: 5

  1. Sanofi-Aventis, 1992, Ambien
  2. Purdue Pharma, 2011, Intermezzo
  3. Farkas RH. Clinical review: dosing for zolpidem products (Reference ID: 3137324). Silver Spring, MD: Food and Drug Administration (FDA), 2013, pp. 1–15.
  4. Sanofi-Aventis, 2008, Ambien
  5. Greenblatt DJ, 2012, Pharmacotherapy, 13, 879

Cited by

See all 39

Metadata

Authors
Norman, J. L., Fixen, D. R., Saseen, J. J., Saba, L. M., & Linnebur, S. A.
Affiliations
  • University of Wisconsin–Madison (US)
  • University of Colorado Anschutz (US)
Corresponding author
Linnebur, Sunny A
Venue
SAGE Open Medicine
Published
2017-01-01
Volume
5
Pages
2050312117707687-2050312117707687
ISSN
2050-3121 (ISSN-L)
OpenAlex
W2610509910
Cited by
38
References
14
Citations by year
2026: 1 · 2025: 1 · 2024: 2 · 2023: 5 · 2022: 6 · 2021: 5 · 2020: 10 · 2019: 4 · 2018: 4
FWCI
2.97
Type
journal article
Language
en
Open access
Licence
  • cc-by-nc
  • journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
Locations
  • SAGE Open Medicine (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Geriatrics and Gerontology › Pharmaceutical Practices and Patient Outcomes
  • Social Sciences › Psychology › Experimental and Cognitive Psychology › Sleep and related disorders
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
Keywords
zolpidem, prescribing patterns, women, young women, sedative-hypnotic drugs, serious adverse events, drug regulation, gender differences in prescribing

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Zolpidem prescribing practices before and after Food and Drug Administration required product labeling changes. https://app.cochat.ai/papers/10.1177/2050312117707687
The paper
Norman, J. L., Fixen, D. R., Saseen, J. J., Saba, L. M., & Linnebur, S. A. (2017). Zolpidem prescribing practices before and after Food and Drug Administration required product labeling changes. SAGE Open Medicine. https://doi.org/10.1177/2050312117707687

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.